Table 5 Crude Kaplan–Meier estimated survival probabilities according to St Gallen adherence and age at diagnosis.

From: Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study

 

St Gallen adherence

5-year overall survival probabilitya

5-year survival probability without distant recurrenceb

Whole sample

In St Gallen

93.0 (90.4–94.9)

91.5 (88.7–93.6)

Over St Gallen

97.1 (94.0–98.6)

96.7 (93.4–98.3)

Under St Gallen

93.1 (90.0–95.2)

92.6 (89.4–94.8)

Total

94.2 (92.7–95.4)

92.9 (91.3–94.3)

Age < 65

In St Gallen

94.9 (92.1–96.7)

93.3 (90.3–95.4)

Over St Gallen

97.6 (94.3–99.0)

97.1 (93.7–98.7)

Under St Gallen

96.3 (93.2–98.0)

95.9 (92.7–97.7)

Total

96.3 (94.9–97.3)

95.1 (93.4–96.3)

Age ≥ 65

In St Gallen

88.1 (81.5–92.4)

86.7 (79.9–91.3)

Over St Gallen

93.6 (76.6–98.4)

93.6 (76.6–98.4)

Under St Gallen

84.9 (76.6–90.5)

84.0 (75.6–89.8)

Total

86.7 (82.0–90.3)

86.4 (81.8–86.4)

  1. aEvent: dead. Censored: patients alive at the end of follow-up.
  2. bEvent: dead or distant recurrence. Censored: patients alive and without distant recurrence at the end of follow-up.